Ascletis Pharma breaks new ground with HK$3.6bn IPO
Chinese firm Ascletis Pharma has launched bookbuilding for a HK$3.58bn ($456.9m) IPO, the first company to take advantage of the Hong Kong Stock Exchange’s new biotechnology-friendly listing regime.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: